// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

EFFICACY AND SAFETY OF UPADACITINIB VERSUS PLACEBO AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PsA-1): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

I. Mcinnes - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

ABT-494

EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY

J. S. Smolen - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Baricitinib

EFFICACY OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH POOR PROGNOSTIC FACTORS: POST HOC ANALYSIS OF FINCH 3

D. Aletaha - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Filgotinib

EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES

P. Helliwell - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Sacroiliitis

guselkumab (IV)

EFFICACY OF NON-TUMOUR NECROSIS FACTOR BIOLOGICS AND TARGETED SYSTEMIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN THE TREATMENT OF PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

A. Bayley - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

EFFICACY, SAFETY AND IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARING PF-06410293 (ADL-PF), AN ADALIMUMAB (ADL) BIOSIMILAR, AND REFERENCE ADL: RESULTS FROM WEEK 26–52 OF A DOUBLE-BLIND, RANDOMISED PHASE 3 STUDY INCLUDING PATIENTS WHO SWITCHED FROM ADL-PF TO REFERENCE ADL AT WEEK

R. Fleischmann - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

EFFICACY OF IXEKIZUMAB ON DISEASE ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND OBJECTIVE SIGNS OF INFLAMMATION, STRATIFIED BY BASELINE CRP/SACROILIAC JOINT MRI STATUS

W. P. Maksymowych - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Non-radiographic axial spondyloarthritis

LY2439821

EFFICACY, SAFETY, AND PHARMACODYNAMIC EFFECTS OF THE BRUTON’S TYROSINE KINASE INHIBITOR, FENEBRUTINIB (GDC-0853), IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS IN A PHASE 2 CONTROLLED STUDY

D. Isenberg - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Fenebrutinib

EHR-INTEGRATED PATIENT-GENERATED HEALTH DATA FOR SYMPTOM MONITORING IN LONG-TERM CONDITIONS: A SYSTEMATIC REVIEW

J. De Fonss Gandrup - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

EMAPALUMAB (ANTI-INTERFERON-GAMMA MONOCLONAL ANTIBODY) IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA)

F. De Benedetti - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Macrophage activation syndrome

Interferon Gamma

EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) - ONE-YEAR FOLLOW-UP STUDY USING MEPOLIZUMAB ANTI-IL5 THERAPY AS A STEROID SPARING THERAPEUTIC APPROACH

A. Egan - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Eosinophilic granulomatosis with polyangiitis

Mepolizumab

EMPOWERING PEOPLE WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES TO BE AT THE HEART OF MEDICAL EDUCATION: A EULAR SCHOOL OF RHEUMATOLOGY INITIATIVE

S. Grealis - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

ENHANCING RHEUMATOLOGY REFERRALS AMONG INFLAMMATORY BOWEL DISEASE PATIENTS WITH SUSPECTED AXIAL SPONDYLOARTHRITIS

C. S. E. Lim - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

ESTABLISHING THE KEY COMPONENTS OF A EULAR PORTFOLIO FOR TRAINING IN RHEUMATOLOGY: A EULAR SCHOOL OF RHEUMATOLOGY INITIATIVE

M. Van Onna - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

EVALUATION OF A 10-WEEK PROGRESSIVE RESISTANCE TRAINING PROGRAMME FOR PEOPLE WITH INFLAMMATORY ARTHRITIS

J. Skeates - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

EULAR-ACR 2019 CLASSIFICATION CRITERIA FOR SLE: CAN WE CLASSIFY USING LABORATORY TESTS ALONE?

S. Dyball - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

EVALUATION OF A NOVEL FAST TRACK PATHWAY FOR GIANT CELL ARTERITIS USING PET IN ADDITION TO TAUS AND TAB FOR EARLY DIAGNOSIS

D. Ludwig - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

N/A

EVALUATING A COMPLEX PACKAGE OF CARE IN THE EAST-MIDLANDS KNEE PAIN FEASIBILITY COHORT RANDOMISED CONTROLLED TRIAL

P. A. Nomikos - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

EULAR POINTS TO CONSIDER FOR THE DETECTION, ASSESSMENT AND MANAGEMENT OF NON-ADHERENCE IN PEOPLE WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES

V. Ritschl - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

EVALUATION OF A PATIENT COMPLETED DISEASE FLARE QUESTIONNAIRE IN PSORIATIC DISEASE

P. Helliwell - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved